Patent 10487333 was granted and assigned to Mologen AG on November, 2019 by the United States Patent and Trademark Office.
The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.